Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes

Current Medicinal Chemistry

Volumn 16, Issue 29, 2009, Pages 3858-3874

  Pal, Manojit ^a  

^a Matrix Laboratories Limited   (India)

Author keywords

Glucokinase; Glucose homeostasis; Glucose lowering effect; Kinase activators; Phosphorylation; Type 2 diabetes

Indexed keywords

2 CYCLOHEXYL 1 (4 METHANESULFONYLPHENYL)CYCLOPROPANECARBOXYLIC ACID 2 THIAZOLYLAMIDE; 4 HYDROXYISOLEUCINE; \PSN 105; ACETAMIDE DERIVATIVE; AGENTS AFFECTING CARBOHYDRATE METABOLISM; AGENTS AFFECTING METABOLISM; AMIDE; ANTIDIABETIC AGENT; ARRY 403; ARRY 588; AZD 1656; AZD 6370; ENZYME ACTIVATOR; GKA 22; GKA 50; GLUCOKINASE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; LY2121260; METFORMIN; NN 9101; ORAL ANTIDIABETIC AGENT; PIRAGLIATIN; PSN 010; PSN 105; R 1440; R 1511; RO 28 1675; RO 4389620; THIOPHENE DERIVATIVE; TTP 355; TTP 399; UNCLASSIFIED DRUG; UREA DERIVATIVE;

CELL DISRUPTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; HUMAN; INSULIN RESISTANCE; LIVER PARENCHYMA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE;

DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME ACTIVATION; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PYRIDINES; THIAZOLES;

EID: 70450195287     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789177993     Document Type: Review

References (81)

1. Eisenbarth, G.S. Update in type 1 diabetes. J. Clin. Endocrinol. Metab., 2007, 92, 2403-2407.
2. Mokdad, A.H.; Ford, E.S.; Bowman, B.A.; Dietz, W.H.; Vinicor, F.; Bales, V.S.; Marks, J.S. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001. JAMA, 2003, 289, 76-79 (doi:10.1001/jama.289.1.76).
3. Moller, D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 2001, 414, 821-827.
4. Xuan, S.; Kitamura, T.; Nakae, J.; Politi, K.; Kido, Y.; Fisher, P.E.; Morroni, M.; Cinti, S.; White, M.F.; Herrera, P.L.; Accili, D.; Efstratiadis, A. Defective insulin secretion in pancreatic β cells lacking type 1 IGF receptor. J. Clin. Invest., 2002, 110, 1011-1019.
5. Reaven, G.M. Pathophysiology of insulin resistance in human disease. Physiol. Rev., 1995, 75, 473-486.
6. (a) Reaven, G.; Abbasi, F.; McLaughlin, T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog. Horm. Res., 2004, 59, 207-223.
7. (b) de Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. FEBS Lett., 2008, 582, 97-105.
8. Ader, M.; Ni, T.C.; Bergman, R.N. Glucose effectiveness assessed under dynamic and steady state conditions. Comparability of uptake versus production components. J. Clin. Invest., 1997, 99, 1187-1199.
9. Tenenbaum A, Motro M, Schwammenthal E. Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int. J. Cardiol., 2004, 97, 167-172. (Pubitemid 39286831)
10. Fowler, M.J. Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes, 2008, 26, 77-82.
11. Grant, P. J. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr. Med. Res. Opin., 2005, 21, Suppl 1:S5-12.
12. Sarti, C.; Gallagher J. The metabolic syndrome: prevalence, CHD risk, and treatment. J. Diabetes Complicat., 2006, 20, 121-132. (Pubitemid 43295378)
13. Gershell, L. Type 2 diabetes market. Nat. Rev. Drug Discov., 2005, 4, 367-368.
14. Bell, D.S.H. A comparison of agents used to manage type 2 diabetes mellitus: Need for reappraisal of traditional approaches. Treat. Endocrinol., 2004, 3, 67-76.
15. (a) Sarabu, R.; Tilley, J. Recent advances in therapeutic approaches to type 2 diabetes. Annu. Rep. Med. Chem., 2005, 40, 167-181.
16. (b) Grimsby, J.; Berthel, S. J.; Sarabu, R. Glucokinase Activators for the Potential Treatment of Type 2 Diabetes. Curr. Top Med. Chem., 2008, 8, 1524-1532.
17. (c) Johnson, T.O; Humphries, P.S. Glucokinase Activators for the Treatment of Type 2 Diabetes. Annu. Rep. Med. Chem., 2006, 41, 141-154.
18. (d) Also see ref 38.
19. Guertin, K.R.; Grimsby, J. Small Molecule Glucokinase Activators as Glucose Lowering Agents: A New Paradigm for Diabetes Therapy. Curr. Med. Chem., 2006, 13, 1839-1843. (Pubitemid 43871760)
20. Coghlan, M.; Leighton, B. Glucokinase activators in diabetes management. Expert Opin. Investig. Drugs, 2008, 17, 145-167.
21. Bloomgarden, Z. T. Insulin resistance: current concepts. Clin. Ther., 1998, 20, 216-231; discussion 215.
22. Genetic aetiology of hyperglycaemia determines response to treatment in diabetes Pearson, E.R.; Starkey, B.J.; Powell, R.J.; Gribble, F.M.; Clark, P.M.; Hattersley, A.T. Lancet, 2003, 362, 1275-1281.
23. LeRoith, D. β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med., 2002, 113, 3-11. (Pubitemid 35335936)
24. Chiasson, J.L.; Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes, 2004, 53(Suppl 3), S34-8. (Pubitemid 39564520)
25. Bogardus, C; Lillioja, S. Pima Indians as a model to study the genetics of NIDDM. J. Cell Biochem., 2004, 48, 337-343.
26. Prentki, M.; Nolan, C.J. Islet β cell failure in type 2 diabetes. J. Clin. Invest., 2006, 116, 1802-1812. (Pubitemid 44033300)
27. Leibowitz, G.; Yuli, M.; Donath, M.Y.; Nesher, R.; Melloul, D.; Cerasi, E.; Gross, D.J.; Kaiser, N. beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes, 2001, 50 (Suppl 1):S113-S117. (Pubitemid 32148231)
28. Unger, R.H.; Zhou, Y.-T. Lipotoxicity of β-Cells in obesity and in other causes of fatty acid spillover. Diabetes, 2001, 50(Suppl 1):S118-S121.
29. Egan, J.M.; Clocquet, A.R.; Elahi, D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab., 2002, 87, 1282-1290. (Pubitemid 36121100)
30. Prentki, M.; Joly, E.; El-Assad, W.; Roduit, R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity. Role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes, 2002, 51 (suppl 3):S405-S413. (Pubitemid 35403424)
31. (a) Printz, R.L.; Magnuson, M.A.; Granner, D.K. Ann. Rev. Nutr., 1993, 13, 463-496.
32. (b) Colowick, S.P., in The Enzymes, Vol.9 (Boyer, P. ed.) Academic Press, New York, N.Y., pages 1-48, 1973.
33. (a) Matschinsky, F.M.; Magnuson, M.A.; Zelent, D.; Jetton, T.L.; Doliba, N.; Han, Y.; Taub, R.; Grimsby, J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes, 2006, 55, 1-12. (Pubitemid 43343293)
34. (b) Chipkin, S. R.; Kelly, K.L.; Ruderman, N.B. in Joslin's Diabetes (Khan, C.R. and Wier, G.C. eds.), Lea and Febiger, Philadelphia, Pa., pages 97-115, 1994.
35. Meglasson, M.D.; Matschinsky, F.M. New perspectives on pancreatic islet glucokinase. Am. J. Physiol., 1984, 246, E1-E13.
36. Printz, R.G., Magnuson, M.A., and Oranner, D.K. in Ann. Rev. Nutrition Vol. 13 (Olson, R.E.; Bier, D.M. and McCormick, D.B. eds.), Annual Review, Inc., Palo Alto, Calif., pages 463-496, 1993.
37. (a) DeFronzo, R.A. Diabetes, 1988, 37, 667-687.
38. (b) Van Schaftingen, E.A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose-6-phosphate and fructose-1-phosphate. Eur. J. Biochem., 1989, 179, 179-184.
39. (c) Alvarez, E., Roncero, I., Chowen, J.A., Vazquez, P. and Blazquez, E. Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain. J. Neurochem., 2002, 80, 45-53. (Pubitemid 34614576)
40. (d) Lynch, R.M.; Tompkins, L.S.; Brooks, H.L.; Dunn-Meynell, A.A.; Levin, B.E. Localization of glucokinase gene expression in the rat brain. Diabetes, 2000, 49, 693-700. (Pubitemid 30339982)
41. (e) Mobbs, C.V.; Kow, L.M.; Yang, X.J. Brain glucosesensing mechanisms: ubiquitous silencing by aglycemia vs. hypothalamic neuroendocrine responses. Am. J. Physiol. Endocrinol. Metab., 2001, 281, E649-E654. (Pubitemid 32948131)
42. (f) Spanswick, D.; Smith, M. A.; Mirshamsi, S.; Routh, V. H.; Ashford, M. L. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat. Neurosci., 2000, 3, 757-758.
43. (g) Kurata, K.; Fujimoto, K.; Sakata, T. Structural evaluation of glucose analogues on feeding elicitation in rat. Metabolism: Clin. Exp., 1989, 38, 46-51. (Pubitemid 19014381)
44. (h) Kurata, K.; Fujimoto, K.; Sakata, T.; Etou, H.; Fukagawa, K. D-glucose suppression of eating after intra-third ventricle infusion in rat. Physiol. Behav., 1986, 37, 615-620.
45. Grimsby, J.; Sarabu, R.; Corbett, W.L.; Haynes, N.-E.; Bizzarro, F. T.; Coffey, J.W.; Guertin, K.R.; Hilliard, D.W.; Kester, R.F.; Mahaney, P.E.; Marcus, L.; Qi, L.; Spence, C.L.; Tengi, J.; Magnuson, M.A.; Chu, C.A.; Dvorozniak, M.T.; Matschinsky, F.M.; Grippo, J.F. Allosteric activators of glucokinase: potential role in diabetes therapy. Science, 2003, 301, 370-373.
46. nd Annual Mastering Medicinal Chemistry: Applying Organic Chemistry to Biological Problems. March 2004, San Francisco. CA.
47. Efanov, A.M.; Barrett, D.G.; Brenner, M.B.; Briggs, S.L.; Delaunois, A.; Durbin, J.D.; Giese, U.; Guo, H.; Radloff, M.; Gil, G.S.; Sewing, S.; Wang, Y.; Weichert, A.; Zaliani, A.; Gromada, J. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology, 2005, 146, 3696-3701. (Pubitemid 41175734)
48. Coope, G.J.; Atkinson, A. M.; Allott, C.; McKerrecher, D.; Johnstone, C.; Pike, K.G.; Holme, P.C.; Vertigan, H.; Gill, D.; Coghlan, M.P.; Leighton, B. Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br. J. Pharmacol., 2006, 149, 328-335. (Pubitemid 44453434)
49. (a) Fyfe, M.C.T.; White, J.; Taylor, A.; Chatfield, R.; Wargent, E.; Printz, R.L.; Sulpice, T.; McCormack, J.G.; Procter, M.J.; Reynet, C.; Widdowson, P.S.; Wong-kai-in, P. Glucokinase activator PSNGK1 displays enhanced antihyperglycemic and insulinotropic actions. Diabetologia, 2007, 50, 1277-1287.
50. (b) Bertram, L.S.; Black, D.; Briner, P.H.; Chatfield, R.; Cooke, A.; Fyfe, M.C.T.; Murray, P.J.; Naud, F.; Nawano, M.; Procter, M.J.; Rakipovski, G.; Rasamison, C.M.; Christine Reynet, C.; Schofield, K.L.; Shah, V.K.; Spindler, F.; Taylor, A.; Roy Turton, R.; Williams, G.N.; Wong-Kai-In,P.; Yasuda, K. SAR, Pharmacokinetics, Safety, and Efficacy of Glucokinase Activating 2-(4-Sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1. J. Med. Chem., 2008, 51, 4340-4345.
51. (c) Briner, P.H.; Fyfe, M.C.T.; Madeley, J.P.; Murray, P.J.; Procter, M.J.; Spindler, F. Enantioselective process. World Patent Application No. WO 2006/016178.
52. (a) Gloyn, A.L. Glucokinase (GCK) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mutat., 2003, 22, 353-362.
53. (b) Johnson, D.; Shepherd, R.M.; Gill, D.; Gorman, T.; Smith, D.M.; Dunne, M.J. Glucose-dependent modulation of insulin and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes, 2007, 56, 1694-1702.
54. Kamata, K.; Mitsuya, M.; Nishimura, T.; Eiki, J.; Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure, 2004, 12, 429-438. (Pubitemid 38353064)
55. Sarabu, R.; Berthel, S.J.; Kester, R.F.; Tilley, J. W. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin. Ther. Patents, 2008, 18, 759-768.
56. Dunten, P.; Swain, A.; Kammlott, U.; Crowther, R.; Lukacs, C.M.; Levin, W.; Reik, L.; Grimsby, J.; Corbett, W.L.; Magnuson, M.A.; Matschinsky, F.M.; Grippo, J.F. Crystal structure of human liver glucokinase bound to a small molecule allosteric activator. In Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Matschinsky, F.M., Magnuson, M.A. Eds.; Karger: Basel, 2004; pp. 145-154.
57. (a) Futamura, M.; Hosaka, H.; Kadotani, A.; Shimazaki, H.; Sasaki, K.; Ohyama, S.; Nishimura, T.; Eiki, J.; Nagata, Y. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J. Biol. Chem., 2006, 281, 37668-37674. (Pubitemid 46042070)
58. (b) Nishimura, T.; Iino, T.; Mitsuya, M.; Bamba, M.; Watanabe, H.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Futamura, M.; Nagata, Y.; Eiki, J.-i. Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators. Bioorg. Med. Chem. Lett., 2009, 19, 1357-1360.
59. (a) Mitsuya, M.; Bamba, M.; Sakai, F.; Watanabe, H.; Sasaki, Y.; Nishimura, T.; Eiki, J.-I. World Patent Application No. WO 2004 081001.
60. (b) Mitsuya, M.; Kamata, K.; Bamba, M.; Watanabe, H.; Sasakai, Y.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Nagata, Y.; Eiki, J.-I.; Nishimura, T., Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg. Med. Chem. Lett. 2009, 19, 2718-2721.
61. Iino, T.; Hashimoto, N.; Nakashima, H.; Takahashi, K.; Nishimura, T.; Eiki, J.-I. World Patent Application No. WO 2004 076420.
62. Brocklehurst, K.J.; Payne, V.A.; Davies, R.A.; Caroll, D.; Vertigan, H.L.; Wightman, H.J.; Aiston, S.; Waddell, I.D.; Leighton, B.; Coghlan, M.P.; Agius, L. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes, 2004, 53, 535-541. (Pubitemid 38270620)
63. McKerrecher, D.; Allen, J.V.; Bowker, S.S.; Boyd, S.; Caulkett, P.W.; Currie, G.S.; Davies, C.D.; Fenwick, M.L.; Gaskin, H.; Grange, E.; Hargreaves, R.B.; Hayter, B.R.; James, R.; Johnson, K.M.; Johnstone, C.; Jones, C.D.; Lackie, S.; Rayner, J. W.; Walker, R. P. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg. Med. Chem. Lett., 2005, 15, 2103-2106. (Pubitemid 40450301)
64. (a) McKerrecher, D.; Allen, J.V.; Caulkett, P.W.; Donald, C.S.; Fenwick, M.L.; Grange, E.; Johnson, K.M.; Johnstone, C.; Jones, C.D.; Pike, K.G.; Rayner, J.W.; Walker, R.P. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. Bioorg. Med. Chem. Lett., 2006, 16, 2705-2709.
65. (b) Iino, T.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Hase gawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.-i.; Nishimura, T. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorg. Med. Chem. Lett., 2009, in press, doi:10.1016/j.bmc.2009.02.038.
66. Weichert, A.G.; Barrett, D.G.; Heuser, S.; Riedl, R.; Tebbe, M.J.; Zaliani, A. World Patent Application No. WO 2004 050645.
67. Efanov, A.M.; Barrett, D.G.; Brenner, M.B.; Briggs, S.L.; Delaunois, A.; Durbin, J.D.; Giese, U.; Guo, H.; Radloff, M.; Gil, G.S.; Sewing, S.; Wang, Y.; Weichert, A.; Zaliani, A.; Gromada, J. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology, 2005, 146, 3696-3701. (Pubitemid 41175734)
68. Weichert, A.G.; Barrett, D.G.; Heuser, S.; Riedl, R.; Tebbe, M.J.; Zaliani, A. World Patent Application No. WO 2004 063194.
69. Daniewski, A.R.; Liu, W.; Radinov, R.N. Process for the preparation of a glucokinase activator. World Patent Application No. WO 2007/115968.
70. Grimsby, J.; Matschinsky, F.M.; Grippo, J.F. Discovery and Actions of Glucokinase Activators. In Glucokinase and Glycemic Disease: From Basic to Novel Therapeutics: Matschinsky, F.M.; Magnuson, M.A.; Karger: Basel, 2004, pp 360-378.
71. Castelhano, A.L.; Dong,H.; Fyfe, M.C.T.; Gardner, L.S.; Kamikozawa, Y.; Kurabayashi, S.; Nawano, M.; Ohashi, R.; Procter, M.J.; Qiu, L.; Rasamison, C. M.; Schofield, K.L.; Shah, V.K.; Ueta, K.; Williams, G.M.; Witter, D.; Yasuda, K. Glucokinase-activating ureas. Bioorg. Med. Chem. Lett., 2005, 15, 1501-1504.
72. Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes - a status review. Curr. Opin. Drug Discov. Devel., 2005, 8, 631-637. (Pubitemid 41224126)
73. Drug candidates in development by phase. DiabesityDigest.com (http://diabesitydigest.com/development/devphase.htm)
74. Broca, C.; Breil, V.; Cruciani-Guglielmacci, C.; Manteghetti, M.; Rouault, C.; Derouet, M.; Rizkalla, S.; Pau, B.; Petit, P.; Ribes, G.; Ktorza, A.; Gross, R.; Reach, G.; Taouis, M. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E463-E471. (Pubitemid 39095880)
75. (a) Boyd, S. A. Arry-588 and Arry-403: Novel glucokinase activators with potent glucose-lowering activity in animals of type 2 diabetes mellitus. SMI Metabolic Diseases Conference, September 26, 2008. http://www.arraybiopharma. com/-documents/Publication/PubAttachment297.pdf.
76. (b) Aicher, T.; Anderson, D.; Boyd, S.; Chicarelli, M.; Condroski, K.; DeWolf, Jr., W.; Fell, J. B.; Fischer, J.; Frank, M.; Galbraith, S.; Garrey, R.; Gunawardana, I.; Hinklin, R.; Hirsch, J.; Lee, P.; Neitzel, N.; Pratt, S.; Singh, A.; Thomas, L.; Turner, T.; Voegtli, W.; Wallace, E.; Williams, L. Discovery of ARRY-588, A Novel Glucokinase Activator with Potent Glucose Lowering Activity in Animal Models of Type 2 Diabetes Mellitus. www.arraybiopharma.com/-documents/Publication/PubAttachment288.pdf
77. Fyfe, M.C.T.; Cawthorne, M.A.; Sennitt, M. V.; Printz, R.L. Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes, 2005, 54 (Suppl. 1), A129, Abs. 522-P.
78. Nonosgita, K.; Ogino, Y.; Ishikawa, M.; Sakai, F.; Nakashima, H.; Nagae, Y.; Tsukahara, D.; Arakawa, K.; Nishimura, T.; Eiki, J.; Arakawa, K. WO 063738 A1, 2005.
79. (a) Ralph, E.C.; Thomas, J.; Almaden, J.; Sun, S. Glucose modulation of glucokinase activation by small molecules. Biochemistry 2008, 17, 5028-5036. (Pubitemid 351575009)
80. (b) Mitsuya, M.; Bamba, M.; Sasaki, Y.; Nishimura, T.; Eiki, J.; Arakawa, K. WO 090332 A1, 2005.
81. Johnson, D.; Shepherd, R.M.; Gill, D.; Smith, D.M.; Dunne, M.J. Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells. Biochem. Soc. Trans., 2007, 35, 1208-1210.